Skip to main content
PMC home page
Evidence-based Complementary and Alternative Medicine : eCAM logoLink to Evidence-based Complementary and Alternative Medicine : eCAM
. 2011 Sep 7;2012:954748. doi: 10.1155/2012/954748

Antiplatelet, Antithrombotic, and Fibrinolytic Activities of Campomanesia xanthocarpa

Jonatas Zeni Klafke 1, 2,2,*, Mariane Arnoldi da Silva 1, 2,2, Mateus Fortes Rossato 1, Gabriela Trevisan 1, Cristiani Isabel Banderó Walker 1, Cláudio Alberto Martins Leal 1, Diego Olschowsky Borges 2, Maria Rosa Chitolina Schetinger 1, Rafael Noal Moresco 3, Marta Maria Medeiros Frescura Duarte 4, Adair Roberto Soares dos Santos 5, Paulo Ricardo Nazário Viecili 2, Juliano Ferreira 1
PMCID: PMC3170703  PMID: 21915188

Abstract

In a previous work based on popular belief, Campomanesia xanthocarpa Berg., popularly known as “guavirova”, showed to have a potential effect in the control of a number of conditions associated with cardiovascular diseases. The aim of the present work was to investigate the effects of C. xanthocarpa extract (CXE) on antiplatelet, antithrombotic and fibrinolytic activities in mice and in human blood. Mice were treated orally for 5 days with CXE or acetylsalicylic acid and at the end of the treatment period animals were challenged for bleeding, acute thromboembolism and ulcerogenic activity. In addition, we have assessed the prothrombin time and activated partial thromboplastin time (aPTT) after oral administration. In in vitro assays, antiplatelet effects of CXE was evaluated on platelet aggregation, and fibrinolytic activity of the extract was observed by mice or human artificial blood clot degradation. Platelet citotoxicity of the extract was also determined by the LDH assay. Results demonstrated that CXE has a significant protective effect on thrombosis. It also inhibits platelet aggregation without demonstrating cytotoxicity on platelets. CXE slightly prolonged aPTT and showed no ulcerogenic activity after oral administration. In addition, CXE showed a fibrinolytic activity. Thus, C. xanthocarpa showed antiplatelet, antithrombotic and fibrinolytic activities in mice.

1. Introduction

The interaction between platelets and blood vessels is important in the development of thrombosis and cardiovascular diseases [1]. Platelets are essential in the maintenance of cardiovascular integrity and in the control of bleeding through forming blood clot. However, they are also implicated in the pathological progression of atherosclerotic lesions and arterial vascular thrombosis [2]. Uncontrolled platelet aggregation is critical in arterial thrombosis and may cause life threatening disorders [3]. Antiplatelet agents are therefore considered as a key tool in the treatment and/or prevention of cardiovascular thrombotic diseases [4]. Although it is well established that aspirin still provides an effective secondary prevention of ischemic cardiovascular disorders, this drug can produce hemorrhagic events and upper gastrointestinal bleeding as major drawbacks [5].

During the past decade, several trials have led to an effort in the search for novel compounds or sources to suppress the platelet aggregation [6, 7]. As a consequence, a number of protective effects of plants against the serious health risks have been summarized due to thrombotic diseases, such as coronary thrombosis and atherosclerosis, and numerous experimental studies have been carried out both in vivo and in vitro [8, 9].

In Brazil, the edible plant Campomanesia xanthocarpa Berg. (Myrtaceae), popularly known as “guavirova,” is present in the Southern region, and is likewise found in Argentina, Paraguay, and Uruguay [10]. Studies have shown that C. xanthocarpa possesses a wide spectrum of physiological effects: the leaves of this plant are used as infusion in folk medicine to treat inflammatory diseases and hypercholesterolemia [11]. Moreover, C. xanthocarpa is empirically used for weight loss and for the control of a number of conditions associated with obesity [12]. One of the most recent studies demonstrated that the C. xanthocarpa produced an effect parallel with the mechanism of oral hypolipemiants, and that this plant showed intense presence of saponins [13], which are widely distributed in plants and have many biological activities, such as antiplatelet activity [14, 15]. Since hypolipemiants also exert antithrombotic effects [16, 17], and although C. xanthocarpa has reduced the blood cholesterol levels in hypercholesterolemic patients [13], until now no information has been available about the antithrombotic effect of C. xanthocarpa.

C. xanthocarpa has been used in the prevention and treatment of cardiovascular diseases based on popular belief and has recently received considerable attention, but the antithrombotic and fibrinolytic activities of this plant still remain unknown. Thus, the aim of the present work was to investigate the effects of C. xanthocarpa on antithrombotic and fibrinolytic activities in mice.

2. Materials and Methods

2.1. Drugs and Reagents

Drugs used in the present study were acetylsalicylic acid (ASA), adenosine diphosphate (ADP), epinephrine and calf collagen type III used for experiments provided from Sigma-Aldrich (St. Louis, USA). Furthermore, streptokinase used in in vitro experiments was obtained from Bergamo (São Paulo, Brazil).

2.2. Plant and Extract Preparation

Leaves were collected in May, 2010 from a Campomanesia xanthocarpa tree in the city of Cruz Alta, RS, Brazil. A Voucher specimen number 1088 was deposited at the Herbarium of University of Cruz Alta. The material collected underwent a cleaning process involving 1 h in a diluted solution of 20% hypochlorite made from a 2% stock solution (final concentration of hypochlorite in diluted solution of 0.4%), immediately followed by washing in running potable water for 15 min. Then, the material was dried at 40–45°C and triturated to a fine powder [13].

In order to carry out the tests, an extract of C. xanthocarpa leaves was prepared. Initially, 500 mg of dry leaves was added to 30 mL of a water solution at 37°C under constant agitation for 30 min. After, the solution was filtered and evaporated to determine total dry content. The final powder was diluted in water and then adjusted to the desired concentration to perform the tests.

2.3. Animal and Human Participants

Male Swiss mice (30–40 g) were used and all animals were housed under standard conditions, with constant temperature (22–24°C) and humidity (55–65%) levels, a 12 h dark-light cycle, and free access to food and water. Animals were acclimatized to the laboratory for at least 1 h before testing. The present study was conducted in accordance with current guidelines for the care of laboratory animals and all procedures were approved by our Institutional Ethics Committee of the Federal University of Santa Maria (number 80/2010). Besides, human blood was collected of six healthful individuals, with showed 30  ± 7 years of age to evaluate in vitro assays, and our research followed guidelines of the Declaration of Helsinki and Tokyo for humans and informed consent was obtained for all the six subjects.

2.4. In Vitro Assays

2.4.1. Blood Manipulation

Blood samples were collected from mice or subjects into Vacutainer (BD Diagnostics, Plymouth, UK) tubes with sodium citrate 3.8% (1 part of citrate : 9 parts of blood). The samples of blood from mice were collected from the hepatic vein. The blood samples were centrifuged for 15 min at 180 ×g to obtain platelet-rich plasma (PRP) or 10 min at 2000 ×g to obtain platelet-poor plasma (PPP).

2.4.2. Platelet Aggregation Test

To evaluate the platelet aggregation, the test was performed by turbidimetric measurement with a Chrono-log optical aggregometer, with AGGRO/LINK Model 810-CA software for Windows version 5.1 [18]. After calibration of the aggregometer, the sample data concerning the assays and reagents were entered on a computer coupled to the equipment, and the sample test was then performed. Aggregation was recorded as the percent change in light transmission: the baseline value was set using PRP and maximal transmission using PPP. PRP was preincubated at 37°C for 4 min with vehicle or the C. xanthocarpa before addition of the platelet agonist, adenosine diphosphate (ADP). Maximal aggregation was obtained stimulating platelet with ADP 10 μM.

2.4.3. Determination of Cytotoxicity

To verify the possible effect of cytotoxicity of C. xanthocarpa on platelets, we analyzed the leakage of lactate dehydrogenase (LDH) from platelets of human. After incubation with test drugs at 37°C for 3 min, aliquots were collected and centrifuged at room temperature for 2 min at 12.000 ×g. A 50 μL aliquot of the resultant supernatant was used to measure the LDH leakage using enzymatic methods with (Labtest, Lagoa Santa-MG, Brazil). The extent of LDH leakage was expressed as % of total enzyme activity measured in platelets completely lysed with 10% sodium dodecyl sulphate (SDS final concentration was 0.05%).

2.4.4. Fibrinolytic Activity

The fibrinolytic activity of the C. xanthocarpa extract was observed by artificial blood clot degradation [19]. An artificial blood clot was made by spontaneous coagulation of 50 μL of fresh mice or human blood in a glass test tube. One hour later, the artificial blood clot was rinsed out repeatedly. The artificial blood clot was dipped in 1, 3, 10, 30, and 100 μg/mL of C. xanthocarpa extract or streptokinase at room temperature. Saline was used as a control. The degradation of the clot was estimated by color development after 1 h at room temperature. Then, red blood cells were lysed by adding 20 μL of triton 5% and then the absorbance of the final solution was read at 560 nm. The amount of color was estimated by linear regression analysis of a standard curve obtained from samples of mice blood properly diluted.

2.5. In Vivo Assays

2.5.1. Animal Treatment

The mice were randomly assigned to distinct groups subjected to the following treatments: 10, 30, or 100 mg/Kg of C. xanthocarpa extract or 100 mg/Kg of ASA. Control animals received only vehicle. Pharmacological treatments were given orally once a day for 5 consecutive days. The last treatment was performed 3 h before the experiment. Animal body weights and general behavior were recorded at the beginning and at the end of the subacute treatment to assess the tolerability of repeated administrations.

2.5.2. Bleeding

The tail transection bleeding was determined applying the method modified [20]. Briefly, tails of mice under light isofluorane anesthesia were transected at 2 mm from the tip and immersed in 1 mL of 37°C saline for 2 min. Red blood cells were lysed by adding 20 μL of triton 5% and absorbance of the solution was read at 560 nm. The amount of hemorrhage was estimated by linear regression analysis of a standard curve obtained from samples of mice blood properly diluted.

2.5.3. Acute Pulmonary Thromboembolism

To verify the acute pulmonary thromboembolism, a modification of method [21] was used. Pulmonary acute thromboembolism was induced in mice by rapid intravenous injection in the tail vein of a mixture of 12 mg/Kg collagen and 1 mg/Kg epinephrine in order to induce about 85% of paralysis in the control group. The loss of the righting reflex for 30 s was considered as indication of paralysis. The occurrence of paralyzed animals was recorded for 15 min after thrombotic mixture injection. Immediately after the last test, mice were euthanized by CO2 chamber.

2.5.4. Ulcerogenic Activity

To evaluate the gastric tolerability of animals after oral administration of C xanthocarpa extract, they were fasted for 18 h prior to the last extract exposure (water ad libitum) and three hours after they were euthanized. The stomachs were opened by cutting along the greater curvature and washed with saline 4°C. Immediately after that, the development of lesions was assessed with support of a magnifying glass. The quantification of gastric mucosal lesions was scored according to their number and size in a scale from 0 up to 8 points, adapted from previous method [22], as follows: (0) without injury, (1) color modification, (2) few petechia/alterations of villous, (3) 1–3 small injuries (≤1 mm length), (4) 1–3 big injuries (≤1 mm length), (5) 1–3 big injuries (>1 mm), (6) more than three small injuries, (7) more than three big injuries, and (8) more than three deep injuries.

2.6. Effect on Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT)

For the measure of aPTT, citrate plasma (0.1 mL) was mixed with 0.1 mL of human placenta lipid extract (Pathrombin; Behringwerke), and the mixture was incubated for 2 min at 37°C. Coagulation was initiated by the addition of 0.1 mL calcium chloride (25 mM), at which point the coagulometer was started and time to clot formation was recorded [23].

For the measure of PT, citrated plasma (0.1 mL) was incubated for 1 min at 37°C, at which point 0.2 mL of human thromboplastin (Thromborel; Behringwerke) was added. The coagulometer was started, and time to clot formation was recorded [23].

2.7. Statistical Analysis

Results were expressed as means ± SEM, except the gastric lesion scores that were expressed as median. Values of effective concentration that induce 50% of effect (EC50) were reported as geometric means accompanied by their respective 95% confidence limits. E max (maximal effect) and I max (maximal inhibition) were calculated based on response of control groups. Data were analyzed by one-way analysis of variance (ANOVA), or t-test when appropriate. Post hoc tests (Student-Newman-Keuls test-SNK) were carried out when appropriate. Differences between groups were analyzed by χ 2 test for pulmonary thromboembolism. Nonparametric Kruskal-Wallis followed by Dunn's test was used to analyze gastric lesion scores. The EC50 values were determined by nonlinear regression analysis using a sigmoidal concentration-response equation of individual experiments using GraphPad Software 5.0 (GraphPad, USA). P < 0.05 was considered indicative of significant differences between groups.

3. Results

3.1. In Vitro Assays

We firstly evaluated the antiplatelet effects of C. xanthocarpa extract using freshly isolated human platelets against agonist-induced platelet aggregation. C. xanthocarpa extract showed a concentration-dependent inhibition of ADP-induced platelet aggregation. The I max observed was 36 ± 5% for the concentration of 1000 μg/mL and the EC50 value of the C. xanthocarpa extract was 35 (15–84) μg/mL compared with the control group (Figure 1(a)).

Figure 1.

Figure 1

Open in a new tab

Effects of Campomanesia xanthocarpa extract on ADP-induced platelet aggregation (a) and on LDH release in platelets (b). Data are shown as mean ± S.E.M. (n = 4–6). *P < 0.05 versus vehicle control (one-way ANOVA, followed by Student Newman-Keuls' test).

To examine the cytotoxicity of C. xanthocarpa extract, we measured the LDH release from platelet for the determination of cell lysis. No concentration tested of C. xanthocarpa extract induced LDH release, while the positive control, SDS 10%, significantly increased the LDH release (Figure 1(b)) reflecting that C. xanthocarpa does not affect cell integrity.

In the evaluation of the fibrinolytic effect, blood clot degradation was observed in all the test tubes of C. xanthocarpa extract or streptokinase, with spreads of red blood cells trapped by multiple fibrins in mice and human blood. In mice blood, the EC50 value to C. xanthocarpa extract and streptokinase was 21 (5–87) μg/mL and 24 (9–64) μg/mL, and the E max observed was 56 ± 9% and 60 ± 14%, respectively, for the concentration of 100 μg/mL of both (Figure 2(a)). In human blood, the EC50 value to C. xanthocarpa extract and streptokinase was 11 (3–33) μg/mL and 4 (1–10) μg/mL, and the E max observed was 62 ± 7% and 70 ± 6%, respectively, for the concentration of 100 μg/mL of both (Figure 2(b)).

Figure 2.

Figure 2

Open in a new tab

Effects of Campomanesia xanthocarpa extract or streptokinase on fibrinolytic activity. Concentration-response curve to mice (a) or human (b) blood. Each point represents the mean of 3 experiments performed in duplicate and the vertical lines represent SEM (nonlinear regression analysis).

3.2. In Vivo Assays

The mean amount of blood lost from control animals 2 min after tail transaction was 5.8 ± 3.1 μL. Mice treated with antithrombotic doses C. xanthocarpa, 30 and 100 mg/Kg/day, showed significant difference from control, losing 24.3 ± 6.6 and 43.4 ± 14.5 μL of blood, respectively. ASA-treated animals lost 51.9 ± 12.9 μL of blood, showing a significant difference when compared to the control group (Figure 3).

Figure 3.

Figure 3

Open in a new tab

Effects of Campomanesia xanthocarpa extract or ASA on bleeding in mice. Data are shown as mean ± SEM (n = 4). *P < 0.05 versus vehicle control (one-way ANOVA, followed by Student Newman-Keuls' test).

C. xanthocarpa had highly significant antithrombotic activity when administered at 100 mg/Kg day since it prevented paralysis induced by events in 80% compared with control. ASA displayed lower efficacy since it showed no significant difference compared to the control to reduce paralysis (Table 1).

Table 1.

Effects of C. xanthocarpa extract on pulmonary thrombosis in mice.

Treatment Dose (mg/Kg) No. of paralysed/
no. of treated mice		 Protection (%)
Vehicle — 9/10 10
C. xanthocarpa 100 2/10a 80
30 4/9a 66.6
10 7/9 33.3
Asprin 100 5/9a 55.5
Open in a new tab

a P < 0.05 versus vehicle control. Data are shown as mean ± SEM (n = 9-10) (χ 2 test).

We also evaluated the possible ulcerogenic activity of C. xanthocarpa extract. None of the doses of the extract were capable of inducing ulcerogenic activity, while aspirin (100 mg/Kg/day, positive control) induced the formation of gastric lesions (the medians (25–75 percentiles)) with lesion scores of 0 (0-1); 4 (3-4); 0 (0-1), 1 (0-1), and 2 (1-2) for vehicle; aspirin: 10 mg/Kg, 30 mg/Kg, and 100 mg/Kg day−1 of C. xanthocarpa extract, respectively.

3.3. Effect on Ex Vivo aPTT and PT

As shown in Table 2, the aPTT and the PT in the vehicle group were 30.90 ± 0.25 sec and 11.33 ± 0.08 sec, respectively. In the C. xanthocarpa-treated groups, the aPPT increased significantly to 32.30 ± 0.91 sec and 33.13 ± 0.63 sec, at the doses of 30 and 100 mg/Kg, respectively, although remaining in normal limits when compared to the vehicle group. There were no significant increases of PT when compared to the vehicle group (Table 2).

Table 2.

Effect of C. xanthocarpa extract on ex vivo aPTT and PT in mice.

Treatment Dose (mg/Kg) aPTT (sec) PT (sec)
Vehicle — 30.90 ± 0.25 11.33 ± 0.08
C. xanthocarpa 10 30.75 ± 0.08 11.30 ± 0.10
30 32.30 ± 0.91a 11.43 ± 0.13
100 33.13 ± 0.63a 11.35 ± 0.08
Open in a new tab

a P < 0.05 versus vehicle control (one-way ANOVA, followed by Student Newman-Keuls' test). Data are shown as mean ± SEM (n = 6).

4. Discussion and Conclusions

Platelets are blood cells that participate in the human primary hemostatic mechanism. Platelet-platelet interaction has the final purpose to produce a platelet thrombus that constitutes the primary hemostatic plug [24]. In addition, platelet adhesion and aggregation on blood vessel walls contribute to the occurrence of thrombosis and emboli formation, and have relation with other cardiovascular diseases [25–27]. Thus, it is important to evaluate platelet function in the thrombosis. Several studies have been carried out to develop antithrombotic agents with improved efficacy for preventing or treating arterial or venous thrombosis [28, 29]. Here, we tested the effect of C. xanthocarpa on platelet aggregation, as well as its antithrombotic and fibrinolytic activities that are still unknown. The results of the present study demonstrated that C. xanthocarpa extract has a significant protective effect in thrombosis once it is capable of inhibiting platelet aggregation without demonstrating cytotoxicity. Furthermore, C. xanthocarpa extract slightly prolonged aPTT, showed a fibrinolytic activity, and did not show ulcerogenic activity after oral administration.

The interactions between platelets and various adhesive proteins, such as collagen, and soluble agonists, such as ADP, provide potential targets for developing antiplatelet agents [30, 31]. The effect of C. xanthocarpa extract on haemostasis in in vivo assays was studied using a model of pulmonary thromboembolism induced by the intravenous injection of collagen plus epinephrine. This model is characterized by the massive activation of circulating platelets and the widespread formation of platelet thrombi in the microcirculation of the lungs leading to disseminated pulmonary microembolism and paralysis of the animal [32]. The oral administration of C. xanthocarpa extract, once a day for 5 days, markedly reduced the percentage of paralysis in a fairly dose-dependent manner. C. xanthocarpa extract resulted to be more effective than ASA in preventing paralysis. During thrombus formation, ADP plays a key role inducting the interaction of membrane receptor glycoprotein IIb–IIIa with fibrinogen, being the most important aggregating agent [26, 33, 34]. Thus, ADP was chosen as agonist to induce platelet aggregation in the study. Results showed that during platelet aggregation, the C. xanthocarpa extract significantly inhibited ADP-induced platelet aggregation. All results suggest that the antithrombotic activities of C. xanthocarpa extract were related at least in part to its ability to inhibit platelet aggregation.

Blood coagulation is not only the result of a complex process initiated by the intrinsic system or the extrinsic system and/or a common pathway, but also a highly regulated process involving interactions between platelets, plasma coagulation factors, and the vessel wall [35]. Inhibitors (anticoagulants) and activators (procoagulant) of blood coagulation may affect any of the factors. The PT test and the aPTT test are used for distinguishing between the effects of test agents on the extrinsic and intrinsic pathways. In the clinical tests of blood coagulation, aPTT is used to evaluate the intrinsic clotting index. A prolonged aPTT usually represents a deficiency in factors VIII, IX, XI, XII, and V or Willebrand's factor. PT is used to evaluate the extrinsic clotting pathway. A prolonged weak PT indicates a deficiency in coagulation factors V, VII, and X [36]. The results reported here show that while the C. xanthocarpa did not have anticlotting effect when examined by the PT test, a slight anticoagulant effect is portrayed by the aPTT test. This indicates that the C. xanthocarpa might not inhibit a factor or factors in the intrinsic pathway of blood coagulation. At this stage, there is no indication of the presence of anticoagulants or procoagulants components in the C. xanthocarpa, since it did not affect the PT. Although C. xanthocarpa has shown slightly anticoagulant effect on aPTT test, this effect did not show clinical significance because the values remained in normal limits.

To further assess the possible effect of C. xanthocarpa on platelet activity, the bleeding in mice was measured. The evaluation of bleeding is a crude test of haemostasis, which is a useful tool to estimate how well platelets interact with blood vessel walls to form blood clots [37]. Here, we demonstrated that C. xanthocarpa extract treatment and ASA affect blood loss. The transactional bleeding time in mice model is sensitive not only to platelet-active compounds, but also to drugs that are capable of influencing the fibrinolytic system [38]. Moreover, C. xanthocarpa extract displayed favorable gastric effects and did not induce gastric lesions after oral administration up to 100 mg/Kg, demonstrating to be safer than ASA. Our results are in accordance with a previous preliminary preclinical study that showed that C. xanthocarpa proved to be effective in preventing gastric ulceration in rats and did not produce toxic symptoms in mice [39]. Besides, the treatment with C. xanthocarpa extract was well tolerated since the treated mice grew similarly to control mice (data not shown).

We also investigated the fibrinolytic activity of the C. xanthocarpa extract, which showed fibrinolytic activity in human and in mice compared to streptokinase. To further investigate the possible mechanism of action of C. xanthocarpa, streptokinase was used as standard. Probably, C. xanthocarpa show a same mechanism similar to the streptokinase. We suggest that the primary role of C. xanthocarpa is the conversion of plasminogen to plasmin. Activated plasmin enzymatically cleaves fibrin, which, with platelets and other hemostatic elements, underlies the pathological processes of the acute occlusive disorders [40]. Besides, when plasmin breaks down fibrin, a number of soluble parts are produced as the D-dimer, that is, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis [41]. Preliminary results of our group demonstrated that both C. xanthocarpa and streptokinase produced D-dimer during fibrinolytic activity. These optimistic results point to the value of further studies in this field. Then with the results presented in the paper we could only assume that C. xanthocarpa might have a similar mechanism of streptokinase, and the result suggested that the C. xanthocarpa extract, besides inhibiting platelet aggregation, also exerted its antithrombotic activity through fibrinolytic activity. Antithrombotic agents acting in only one pathway of thrombosis formation have limited efficacy in treating arterial thrombotic diseases [42]. Hence, the C. xanthocarpa extract with a combination of antiplatelet aggregation, antithrombotic, and fibrinolytic activities may be effective in preventing thrombus formation through several pathways.

Saponins are widely distributed in plants and have many biological activities, such as antiplatelet activity [14, 15]. The phytochemical components responsible for C. xanthocarpa antiplatelet effect are still unknown, but preliminary studies demonstrated the presence of tannins and flavonoids (quercetin, myricetin, quercitrin, and rutin) in this plant [39, 43]. Moreover, recent preliminary phytochemical analysis of C. xanthocarpa by our group indicated the intense presence of saponins, tannins, and terpenes and small presence of flavonoids [13]. Thus, we suggest that C. xanthocarpa bioactive compounds may be inhibiting platelet aggregation.

In conclusion, the C. xanthocarpa extract demonstrated antiplatelet, antithrombotic, and fibrinolytic activities in mice. The antithrombotic activity of C. xanthocarpa extract derived probably from antiplatelet aggregation and fibrinolytic activities. The present research showed quite optimistic results pointing to the value of further studies in this field.

Conflicts of Interests

The authors declared that there is no conflict of interests.

Acknowledgments

This study was supported by Conselho Nacional de Desenvolvimento Científico (CNPq) (Brazil). The fellowships from CNPq and CAPES are also acknowledged.

References

  • 1.Gorden JL. Platelets in perspective. In: Gorden JL, editor. Platelets in Biology and Pathology. Amsterdam, the Netherlands: North-Holland Press; 1981. pp. 1–17. [Google Scholar]
  • 2.May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(3):s5–s10. doi: 10.1161/ATVBAHA.107.158915. [DOI] [PubMed] [Google Scholar]
  • 3.Davies MJ, Thomas AC. Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. British Heart Journal. 1985;53(4):363–373. doi: 10.1136/hrt.53.4.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. British Journal of Haematology. 2008;142(4):515–528. doi: 10.1111/j.1365-2141.2008.07233.x. [DOI] [PubMed] [Google Scholar]
  • 5.Johnson S. Known knowns and known unknowns: risks associated with combination antithrombotic therapy. Thrombosis Research. 2008;123(1):S7–S11. doi: 10.1016/j.thromres.2008.08.011. [DOI] [PubMed] [Google Scholar]
  • 6.Lau AJ, Toh DF, Chua TK, Pang YK, Woo SO, Koh HL. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium . Journal of Ethnopharmacology. 2009;125(3):380–386. doi: 10.1016/j.jep.2009.07.038. [DOI] [PubMed] [Google Scholar]
  • 7.Ryu KH, Han HY, Lee SY, et al. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thrombosis Research. 2009;124(3):328–334. doi: 10.1016/j.thromres.2009.02.010. [DOI] [PubMed] [Google Scholar]
  • 8.Wang HX, Ng TB. Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. Life Sciences. 1999;65(25):2663–2677. doi: 10.1016/s0024-3205(99)00253-2. [DOI] [PubMed] [Google Scholar]
  • 9.Kris-Etherton PM, Hecker KD, Bonanome A, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. American Journal of Medicine. 2002;113(9):S71–S88. doi: 10.1016/s0002-9343(01)00995-0. [DOI] [PubMed] [Google Scholar]
  • 10.Lorenzi H. Árvores Brasileiras: Manual de Identificação e Cultivo de Plantas Arbóreas do Brasil. São Paulo, Brazil: Instituto Plantarum de Estudos da Flora; 1992. [Google Scholar]
  • 11.Alice CB, Siqueira NCS, Mentz LA, Brasil e Silva GAA, José KFD. Plantas Medicinais De Uso Popular: Atlas Farmacognóstico. Canoas, Brazil: Ulbra; 1995. [Google Scholar]
  • 12.Dickel ML, Rates SM, Ritter MR. Plants popularly used for loosing weight purposes in Porto Alegre, South Brazil. Journal of Ethnopharmacology. 2007;109(1):60–71. doi: 10.1016/j.jep.2006.07.003. [DOI] [PubMed] [Google Scholar]
  • 13.Klafke JZ, da Silva MA, Panigas TF, et al. Effects of Campomanesia xanthocarpa on biochemical, hematological and oxidative stress parameters in hypercholesterolemic patients. Journal of Ethnopharmacology. 2010;127(2):299–305. doi: 10.1016/j.jep.2009.11.004. [DOI] [PubMed] [Google Scholar]
  • 14.Rao AV, Gurfinkel DM. The bioactivity of saponins: triterpenoid and steroidal glycosides. Drug Metabolism and Drug Interactions. 2000;17(1–4):211–235. doi: 10.1515/dmdi.2000.17.1-4.211. [DOI] [PubMed] [Google Scholar]
  • 15.Sparg SG, Light ME, Van Staden J. Biological activities and distribution of plant saponins. Journal of Ethnopharmacology. 2004;94(2-3):219–243. doi: 10.1016/j.jep.2004.05.016. [DOI] [PubMed] [Google Scholar]
  • 16.Rossiello MR, Momi S, Caracchini R, et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. Journal of Thrombosis and Haemostasis. 2005;3(11):2554–2562. doi: 10.1111/j.1538-7836.2005.01605.x. [DOI] [PubMed] [Google Scholar]
  • 17.Fenton JW, Jeske WP, Catalfamo JL, Brezniak DV, Moon DG, Shen GX. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry. 2002;67(1):85–91. doi: 10.1023/a:1013956215394. [DOI] [PubMed] [Google Scholar]
  • 18.Born GVR, Cross MJ. The aggregation of blood platelets. The Journal of Physiology. 1963;95:168–178. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Omura K, Hitosugi M, Zhu X, Ikeda M, Maeda H, Tokudome S. A newly derived protein from Bacillus subtilis natto with both antithrombotic and fibrinolytic effects. Journal of Pharmacological Sciences. 2005;99(3):247–251. doi: 10.1254/jphs.fp0050408. [DOI] [PubMed] [Google Scholar]
  • 20.Dejana E, Callioni A, Quintana A, De Gaetano G. Bleeding time in laboratory animals. II. A comparison of different assay conditions in rats. Thrombosis Research. 1979;15(1-2):191–197. doi: 10.1016/0049-3848(79)90064-1. [DOI] [PubMed] [Google Scholar]
  • 21.Di Minno G. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. Journal of Pharmacology and Experimental Therapeutics. 1983;225(1):57–60. [PubMed] [Google Scholar]
  • 22.Walker CIB, Trevisan G, Rossato MF, et al. Antinociceptive activity of Mirabilis jalapa in mice. Journal of Ethnopharmacology. 2008;120(2):169–175. doi: 10.1016/j.jep.2008.08.002. [DOI] [PubMed] [Google Scholar]
  • 23.Mousa SA. In vitro methods of evaluating antithrombotics and thrombolytics. Methods in Molecular Biology. 2010;663:1–28. doi: 10.1007/978-1-60761-803-4_1. [DOI] [PubMed] [Google Scholar]
  • 24.Jin YR, Hwang KA, Cho MR, et al. Anti-platelet and anti-thrombotic activities of CP 201, a newly synthesized 1, 4- naphthoquinone derivative. Vascular Pharmacology. 2004;41:35–41. doi: 10.1016/j.vph.2004.04.001. [DOI] [PubMed] [Google Scholar]
  • 25.Ruggeri Z. Platelets in atherothrombosis. Nature Medicine. 2002;8(11):1227–1234. doi: 10.1038/nm1102-1227. [DOI] [PubMed] [Google Scholar]
  • 26.Tang Z, Wang Y, Xiao Y, Zhao M, Peng S. Anti-thrombotic activity of PDR, a newly synthesized L-Arg derivative, on three thrombosis models in rats. Thrombosis Research. 2003;110(2-3):127–133. doi: 10.1016/s0049-3848(03)00339-6. [DOI] [PubMed] [Google Scholar]
  • 27.Michelson AD, Frelinger AL, III, Furman MI. Current Options in Platelet Function Testing. American Journal of Cardiology. 2006;98(10):S4–S10. doi: 10.1016/j.amjcard.2006.09.008. [DOI] [PubMed] [Google Scholar]
  • 28.Lee JJ, Jin YR, Lim Y, et al. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization. Vascular Pharmacology. 2006;45(3):148–153. doi: 10.1016/j.vph.2006.04.003. [DOI] [PubMed] [Google Scholar]
  • 29.Jin YR, Han XH, Zhang YH, et al. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-γ2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis. 2007;194(1):144–152. doi: 10.1016/j.atherosclerosis.2006.10.011. [DOI] [PubMed] [Google Scholar]
  • 30.Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery. 2003;2(1):15–28. doi: 10.1038/nrd985. [DOI] [PubMed] [Google Scholar]
  • 31.Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the “magic bullet”. Nature Reviews Drug Discovery. 2003;2:1–15. doi: 10.1038/nrd1198. [DOI] [PubMed] [Google Scholar]
  • 32.Gresele P, Corona C, Alberti P, Nenci GP. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thrombosis and Haemostasis. 1990;64(1):80–86. [PubMed] [Google Scholar]
  • 33.Wu CC, Wang TW, Wang WY, Hsieh PW, Wu YC. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets. European Journal of Pharmacology. 2005;527(1–3):37–43. doi: 10.1016/j.ejphar.2005.10.023. [DOI] [PubMed] [Google Scholar]
  • 34.Park WH, Ahn JC, Kim HM, Lee YC, Kim CH. Effects of a Korean herbal formulation, Silsosangami, consisting of seven medicinal herbs, and its seven herbs on endotoxin-induced experimental thrombosis in Rats. Phytotherapy Research. 2004;18(3):224–229. doi: 10.1002/ptr.1429. [DOI] [PubMed] [Google Scholar]
  • 35.Renné T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells, Molecules, and Diseases. 2006;36(2):148–151. doi: 10.1016/j.bcmd.2005.12.014. [DOI] [PubMed] [Google Scholar]
  • 36.Azevedo AP, Farias JC, Costa GC, et al. Anti-thrombotic effect of chronic oral treatment with Orbignya phalerata Mart. Journal of Ethnopharmacology. 2007;111(1):155–159. doi: 10.1016/j.jep.2006.11.005. [DOI] [PubMed] [Google Scholar]
  • 37.Henry JB. Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, Pa, USA: W. B. Saunders; 1996. [Google Scholar]
  • 38.Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thrombosis Research. 2001;101(3):159–170. doi: 10.1016/s0049-3848(00)00398-4. [DOI] [PubMed] [Google Scholar]
  • 39.Markman BEO, Bacchi EM, Kato ETM. Antiulcerogenic effects of Campomanesia xanthocarpa . Journal of Ethnopharmacology. 2004;94(1):55–57. doi: 10.1016/j.jep.2004.04.025. [DOI] [PubMed] [Google Scholar]
  • 40.Perler B. Thrombolytic therapies: the current state of affairs. Journal of Endovascular Therapy. 2005;12(2):224–232. doi: 10.1583/04-1438.1. [DOI] [PubMed] [Google Scholar]
  • 41.Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13):2878–2887. doi: 10.1182/blood-2008-06-165845. [DOI] [PubMed] [Google Scholar]
  • 42.Paikin JS, Eikelboom JW, Cairns JA, Hirsh J. New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology. 2010;7(9):498–509. doi: 10.1038/nrcardio.2010.101. [DOI] [PubMed] [Google Scholar]
  • 43.Schmeda-Hirschmann G. Flavonoids from Calycorectes, Campomanesia, Eugenia and Hexachlamys species. Fitoterapia. 1995;66(4):373–374. [Google Scholar]

Articles from Evidence-based Complementary and Alternative Medicine : eCAM are provided here courtesy of Wiley

RESOURCES